A

Amgen

Biotech company creating biologic medicines

Associate Contracts & Pricing - Chargebacks

Full-TimeUpdated on 10/2/2026
No salary listed
Mid
Master's
Hyderabad, Telangana, India
In Person

About the job

Requirements
  • A master's degree in finance, accounting, commerce, business administration, economics, life sciences, or a related discipline.
  • Three to six years of experience in pharmaceutical commercial operations, chargebacks, contracts and pricing, managed markets, finance, revenue management, sales operations, or related business operations.
  • Strong Excel, reporting, analytical, and documentation skills.
  • Ability to manage multiple priorities, meet timelines, and work effectively in a controlled, deadline-driven environment.
Responsibilities
  • Support day-to-day execution of U.S. chargeback operations, including electronic data interchange claim review, validation, adjudication support, payment processing support, dispute follow-up, deduction research, and financial reconciliation activities.
  • Review and validate chargeback claims in Model N / GCPS for contract pricing, customer eligibility, membership alignment, wholesaler authorization, and product-level details.
  • Research and resolve chargeback exceptions, including duplicate submissions, customer-not-found errors, wholesaler eligibility issues, pricing discrepancies, membership mismatches, 340B validation issues, and contract authorization exceptions.
  • Maintain accurate documentation of claim decisions, validation outcomes, supporting evidence, and follow-up actions.
  • Review chargeback dispute and exception reports and complete required research within established timelines.
  • Use Model N / GCPS, SAP, HIBCC, HRSA, Tableau, customer master data, contract records, and wholesaler documentation to resolve claim errors and exceptions.
  • Coordinate with Membership, MDM, Government Pricing, Contracting, and Market Access teams to resolve customer, pricing, eligibility, and contract-related issues.
  • Reprocess corrected claims and ensure timely closure of open items, aged exceptions, and escalated issues.
  • Support manager review of complex chargeback claims involving high-value transactions, large discrepancies, manual adjustments, pricing exceptions, or unusual wholesaler activity.
  • Validate invoices, claim adjustments, comments, and supporting documentation to assist accurate adjudication decisions.
  • Prepare and maintain audit-ready documentation, approval evidence, process records, and workpapers supporting SOX-controlled activities.
  • Support SOP maintenance, process documentation, governance logs, and structured operational records.
  • Support resolution of wholesaler disputes, claim denials, deduction inquiries, customer eligibility questions, and operational issues.
  • Review rejected claims, evaluate supporting evidence, prepare rationale, and document dispute outcomes.
  • Collaborate with wholesalers, GPOs, specialty groups, internal stakeholders, and U.S.-based partners to support timely and accurate issue resolution.
  • Identify recurring wholesaler submission errors and provide inputs for root-cause analysis and process improvement.
  • Investigate wholesaler deductions using supporting claim details, open deduction reports, prior communications, and GCPS / SAP data.
  • Analyze deductions to determine validity, identify root causes, and support recovery or closure recommendations.
  • Partner with Treasury, Finance, and the Chargebacks Manager on offset processing, payment recovery follow-up, and deduction status tracking.
  • Maintain deduction trackers and support reporting on open items, recovery trends, and unresolved exposures.
  • Prepare chargeback operational reporting, trend analysis, KPI inputs, and ad hoc analyses for stakeholders.
  • Support customer, wholesaler, product, contract, indirect sales, disputed transaction, and missing chargeback analyses.
  • Identify recurring patterns in claim errors, disputes, deductions, eligibility issues, and pricing discrepancies.
  • Contribute to dashboard development, reporting improvements, and manual effort reduction initiatives.
  • Ensure compliance with SOX controls, internal policies, pricing governance requirements, audit standards, and applicable pharmaceutical contracting regulations.
  • Identify operational, compliance, financial, and data integrity risks and lead mitigation and remediation efforts.
  • Support internal, external, and SOX audit activities and drive closure of audit observations.
  • Support process improvement, automation, user acceptance testing, workflow enhancement, SOP updates, and standardization initiatives.
Desired Qualifications
  • Pharmaceutical or biotechnology industry experience.
  • Knowledge of U.S. pharmaceutical chargebacks, market access contracting, reimbursement, customer eligibility, and membership management.
  • Experience with Model N Revenue Management, SAP, Revitas, or comparable platforms.
  • Working knowledge of Government Pricing, Class of Trade, 340B, GPO contracting, wholesaler operations, and commercial contracting.
  • Experience supporting U.S. pharmaceutical commercial operations, contracts and pricing operations, sales operations, or related business operations in a regulated or highly controlled environment.
  • Experience supporting SOX controls, compliance programs, audits, and operational governance activities.
  • Strong problem-solving, communication, stakeholder management, and follow-through skills.
  • Experience working with U.S.-based stakeholders and distributed global operating models.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.